Patients with depression can live with symptoms for a long period of time before finding an option that works. One possibility for patients who are unable to find relief through pharmacology is transcranial magnetic stimulation. An expert offers his view on this form of treatment.
Patients with PD with gait impairment can benefit from compensation strategies, but many have limited awareness regarding the full spectrum of available strategies.
Results showed that at the end of the 12-month period, treatment with Invega Hafyera was found to be noninferior to Invega Trinza with regard to the primary endpoint.
For adults with schizophrenia and related psychotic disorders, the polygenic risk score does not improve the performance of predictive models for outcomes.
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
